ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The μ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy

ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The μ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy

Sergio D Bergese,1 Marek Brzezinski,2 Gregory B Hammer,3 Timothy L Beard,4 Peter H Pan,5 Sharon E Mace,6 Richard D Berkowitz,7 Kristina Cochrane,8 Linda Wase,8 Harold S Minkowitz,9 Ashraf S Habib10 1School of Medicine, Stony Brook University, Stony Brook, NY, USA; 2School of Medicine, University of...

Full description

Bibliographic Details
Main Authors: Bergese SD, Brzezinski M, Hammer GB, Beard TL, Pan PH, Mace SE, Berkowitz RD, Cochrane K, Wase L, Minkowitz HS, Habib AS
Format: Article
Language:English
Published: Dove Medical Press 2019-11-01
Series:Journal of Pain Research
Subjects:
acute pain
analgesia
patient-controlled
clinical trial
Online Access:https://www.dovepress.com/athena-a-phase-3-open-label-study-of-the-safety-and-effectiveness-of-o-peer-reviewed-article-JPR

Internet

https://www.dovepress.com/athena-a-phase-3-open-label-study-of-the-safety-and-effectiveness-of-o-peer-reviewed-article-JPR

Similar Items